MILESTONE
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
What will happen during the trial?
While AHCT is an important treatment strategy for patients with multiple myeloma, from a safety standpoint, AHCT is associated with both acute toxicities that reduce quality of life and long-term toxicities that may limit life expectancy for some patients. Additionally its benefit in patients without evidence of minimal residual disease (MRD) is unknown.
We propose to examine MRD response as a strategy to defer AHCT in a systematic manner.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 20 patients (estimated)
- Sponsors
- University of Alabama at Birmingham
- Tags
- Monoclonal Antibody, CD38
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1209
- NCT Identifier
- NCT04991103
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.